Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment
Sponsor: Nektar Therapeutics
Location(s): United States
The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild or moderate hepatic impairment. Safety and PK data from patients with mild or moderate hepatic impairment will be compared with a control group consisting of patients with normal hepatic function.